ConvaTec Group PLC (CTEC.L) Stock
ConvaTec Group PLC

Company profile
ConvaTec Group reported revenue of $2.44 billion for fiscal year 2025, up 6.5% from fiscal year 2024, and net income of $175.00 million. That is a net profit margin of 7.2% for fiscal year 2025. US was its largest region in fiscal year 2025, with 37% of revenue. Our analysis of its filings shows revenue growing from $2.14 billion in fiscal year 2023 to $2.44 billion in fiscal year 2025, 6.7% a year on average. ConvaTec Group reports about 10,000 full-time employees.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About ConvaTec Group PLC
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Largest shareholders
- Black Creek Investment Management, Inc.5.18%
- Artisan Partners LP5.04%
- Massachusetts Financial Services Co.5.03%
- Capital Research & Management Co. (Global Investors)4.90%
- Pelham Capital Ltd.4.82%
Share of the company, as of September 25, 2026
Leadership
- Jonathan Peter Mason — CEO & Director, 61
- Kjersti Grimsrud Biotechnology, M.Sc. — President & COO of Infusion Care, 64
- Bruno Pinheiro — President & COO of Ostomy Care
- Fiona Victoria Ryder — CFO & Director, 50
- Peter Jarvis — Chief Operations Officer
How much revenue does ConvaTec Group make?
ConvaTec Group reported $2.44 billion in revenue for fiscal year 2025, up 6.5% from $2.29 billion in fiscal year 2024.
Where does ConvaTec Group make most of its revenue?
US: 37% of revenue by region in fiscal year 2025, followed by Other (37%).
What companies are similar to ConvaTec Group?
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Advanced Medical Solutions Group plc (AMS.L), SDI Group plc (SDI.L), Verici Dx plc (VRCI.L).
How has ConvaTec Group's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, $2.04 billion; FY2022, $2.07 billion; FY2023, $2.14 billion; FY2024, $2.29 billion; FY2025, $2.44 billion.
Company Information
Data as of .
How to cite: DataPorium, “ConvaTec Group PLC (CTEC.L)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/CTEC.L